Icentia enrolls the first patient in its 300-patient, multicenter clinical study

Icentia is pleased to announce that the first patient was officially enrolled in its 2-year, 300-patient, multi-center clinical study to evaluate the CardioStat, a unique electrocardiography monitoring solution for patients with suspected cardiac arrhythmia.

This study is the result of a collaboration between Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) who have chosen to join their efforts in July of 2012 to test the CardioStat solution. The study follows a protocol formally approved by the IUCPQ ethics committee on June 2013 (approval #20898).

The Principal Investigator for this study is cardiologist Dr Isabelle Nault from the IUCPQ. Dr Nault also benefits from a collaboration with 6 cardiologists from the same institute. This study was made possible with the financial support of the Fondation de l'IUCPQ.

Icentia receives support from the National Research Council of Canada

Icentia Inc. is pleased to announce it will obtain the support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to develop its CardioStat suite of cardiology products and services. Icentia welcomes the advisory services and the financial support provided by NRC-IRAP as it will surely help accelerate the launch of the first CardioStat commercial version.

For more information about IRAP: http://www.nrc-cnrc.gc.ca/eng/irap/services/index.html

Icentia receives authorization from Health Canada to distribute the CardioStatTM in the context of its experimental study

Icentia has obtained authorization under the Medical Devices Regulations of Canada for the sale of the CardioStat in the context of the experimental study it is conducting with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ).

Icentia and IUCPQ are collaborating in this study to evaluate the performance of the CardioStat electrocardiography monitor and its efficacy at detecting most common types of atrial arrhythmias. Icentia plans to enrol the first patient of this multicenter, 300-patient study early this summer.

Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec to launch a 300-patient multicentric clinical study to evaluate the efficacy of the CardioStat

In collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Icentia is embarking on a clinical study to evaluate the CardioStatTM, a unique electrocardiography solution for patients with suspected cardiac arrhythmia.

Specifically, the study will evaluate the performance of the CardioStatTM electrocardiography monitor and its efficacy at detecting most common types of atrial arrhythmias. In a three-phase, 2-year multi-center clinical study, set to begin this spring, approximately 300 patients will be enrolled and followed for suspected arrhythmia with the CardioStatTM electrocardiography monitor.

The study will be under the supervision of cardiologist Dr Isabelle Nault from IUCPQ. Dr Nault is the Principal Investigator. She will also be receiving the support from a group of six other cardiologists from IUCPQ. This study was made possible with the financial support of the Fondation de l'IUCPQ.

IUCPQ's mission is to stop epidemic obesity and the progression of cardiac and pulmonary diseases. Learn more at http://www.iucpq.qc.ca.

Icentia receives financial support from the Ministère des Finances et de l'Économie of the province of Quebec for the development of the CardioStat

QUEBEC, November 4, 2012 - Icentia is pleased to announce that it has won the support of the Ministère des Finances et de l'Économie of the province of Quebec through its Programme d'Appui à l'Innovation. This important contribution will support Icentia in the design of its electrocardiography recorder, CardioStatTM, and will assist with regulatory elements and intellectual property issues.

The main objective of the program is to support Quebec companies in the development and marketing of new products and innovative processes in technology.

For more information on the PAI program, click here.

About Icentia
Icentia is a combined medical devices and service company based in Canada. It develops a line of innovative solutions for healthcare institutions in the field of ambulatory electrocardiography and pulse oximetry. Icentia's mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec have agreed to collaborate in the testing of an innovative cardiac rhythm recorder.

QUEBEC, July 29, 2012 - Icentia and the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) have agreed to collaborate for the testing of a unique electrocardiography monitoring solution for patients with suspected cardiac arrhythmia. This agreement will allow Icentia to benefit from IUCPQ's expertise during the device's development and will eventually lead to a clinical study to test efficacy.

For Icentia, involving such an important clinical partner at an early stage of a product development is a key element of its strategy. This approach ensures that healthcare institutions are provided with innovative, real-world solutions that are perfectly adapted to their requirements.

The IUCPQ is a leader in specialized and ultra-specialized care in cardiology. It is the healthcare center with the largest clinical volume in tertiary cardiology in Canada. IUCPQ's mission is to stop epidemic obesity and the progression of cardiac and pulmonary diseases. Learn more at http://www.iucpq.qc.ca.